<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="originated [2â€&quot;4] from the Abigail Alliance for Better Access to" exact="Developmental" post="Drugs versus von Eschenbach. Due to Abigailâ€™s high expression"/>
 <result pre="expression of EGFR, her oncologist recommended Abigail for her terminal" exact="head and neck cancer" post="to try an investigational EGFR-targeted drug, C222 (Erbitux), which"/>
 <result pre="of EGFR, her oncologist recommended Abigail for her terminal head" exact="and neck" post="cancer to try an investigational EGFR-targeted drug, C222 (Erbitux),"/>
 <result pre="her oncologist recommended Abigail for her terminal head and neck" exact="cancer" post="to try an investigational EGFR-targeted drug, C222 (Erbitux), which"/>
 <result pre="which was then undergoing clinical trial for the treatment of" exact="colorectal cancer." post="Due to her ineligibility to participate in the clinical"/>
 <result pre="a constitutional right. Abigailâ€™s tragic story was one of the" exact="primary" post="precursors and a â€œcatalystâ€� that inspired patients and non-patients,"/>
 <result pre="Act [5]. The legislation overcame many of the regulatory barriers," exact="limited" post="the risks to the sponsor while implementation of the"/>
 <result pre="annual summary report; (iii) the patient in most cases has" exact="limited" post="understanding of the informed consent due to complexity and"/>
 <result pre="safety of the experimental drug that may potentially result in" exact="limited" post="information for the health and safety of the public."/>
 <result pre="and occasionally overlooked is comorbidity; it is quite common among" exact="cancer" post="patients and it can potentially affect the treatment outcome,"/>
 <result pre="drugs in patients with morbidity may thus be risky or" exact="limited" post="unless the experimental drug has gone through further rigorous"/>
 <result pre="for monitoring efficacy and safety of the therapy. Treatment of" exact="metastatic" post="cancer patients with comorbidity using experimental drugs would be"/>
 <result pre="monitoring efficacy and safety of the therapy. Treatment of metastatic" exact="cancer" post="patients with comorbidity using experimental drugs would be even"/>
 <result pre="few eligible patients under the early access programs, the sponsorsâ€™" exact="primary" post="goal has been to have full FDA approval of"/>
 <result pre="From 2003 to 2005, the SFDA approved H101, experimental oncolytic" exact="viral" post="therapy for head and neck cancer, an angiogenic Endostar"/>
 <result pre="2005, the SFDA approved H101, experimental oncolytic viral therapy for" exact="head and neck cancer," post="an angiogenic Endostar inhibitor for treating non-small cell lung"/>
 <result pre="the SFDA approved H101, experimental oncolytic viral therapy for head" exact="and neck" post="cancer, an angiogenic Endostar inhibitor for treating non-small cell"/>
 <result pre="neck cancer, an angiogenic Endostar inhibitor for treating non-small cell" exact="lung cancer" post="and Gendicine for treating head and neck cancer [9â€&quot;11]."/>
 <result pre="cancer, an angiogenic Endostar inhibitor for treating non-small cell lung" exact="cancer" post="and Gendicine for treating head and neck cancer [9â€&quot;11]."/>
 <result pre="for treating non-small cell lung cancer and Gendicine for treating" exact="head and neck cancer" post="[9â€&quot;11]. However, in December, 2019, the Drug Administration Law"/>
 <result pre="treating non-small cell lung cancer and Gendicine for treating head" exact="and neck" post="cancer [9â€&quot;11]. However, in December, 2019, the Drug Administration"/>
 <result pre="cell lung cancer and Gendicine for treating head and neck" exact="cancer" post="[9â€&quot;11]. However, in December, 2019, the Drug Administration Law"/>
 <result pre="RNA viruses including the Ebola virus by interfering with the" exact="viral" post="polymerase enzyme. Remdesivir is currently being used as an"/>
 <result pre="from 1991 to 2002 have been reviewed [14] involving a" exact="total" post="of 460 trials and 11,935 participants. The participants were"/>
 <result pre="merits such as higher efficacy and safety due to a" exact="lower" post="death rate if the investigational drug is combined with"/>
 <result pre="TableÂ 1 Example of anti-cancer drugs phase I/II completed studies" exact="Disease" post="or conditions Interventions Colorectal cancer Drug: Capecitabine and Aflibercept"/>
 <result pre="anti-cancer drugs phase I/II completed studies Disease or conditions Interventions" exact="Colorectal cancer" post="Drug: Capecitabine and Aflibercept Metastatic breast cancer Drug: Tivozanib"/>
 <result pre="drugs phase I/II completed studies Disease or conditions Interventions Colorectal" exact="cancer" post="Drug: Capecitabine and Aflibercept Metastatic breast cancer Drug: Tivozanib"/>
 <result pre="or conditions Interventions Colorectal cancer Drug: Capecitabine and Aflibercept Metastatic" exact="breast cancer" post="Drug: Tivozanib (AV-951)â€‰+â€‰paclitaxel Bladder cancer Biological: Vesigenurtaclel-1 (HS-410) Biological:"/>
 <result pre="conditions Interventions Colorectal cancer Drug: Capecitabine and Aflibercept Metastatic breast" exact="cancer" post="Drug: Tivozanib (AV-951)â€‰+â€‰paclitaxel Bladder cancer Biological: Vesigenurtaclel-1 (HS-410) Biological:"/>
 <result pre="Drug: Capecitabine and Aflibercept Metastatic breast cancer Drug: Tivozanib (AV-951)â€‰+â€‰paclitaxel" exact="Bladder" post="cancer Biological: Vesigenurtaclel-1 (HS-410) Biological: Placebo Biological: BCG Ovarian"/>
 <result pre="Capecitabine and Aflibercept Metastatic breast cancer Drug: Tivozanib (AV-951)â€‰+â€‰paclitaxel Bladder" exact="cancer" post="Biological: Vesigenurtaclel-1 (HS-410) Biological: Placebo Biological: BCG Ovarian cancer"/>
 <result pre="Bladder cancer Biological: Vesigenurtaclel-1 (HS-410) Biological: Placebo Biological: BCG Ovarian" exact="cancer" post="Primary peritoneal Drug: Pemetrexedâ€&quot;Phase 1 Drug: Carboplatinâ€&quot;Phase 1 Drug:"/>
 <result pre="cancer Biological: Vesigenurtaclel-1 (HS-410) Biological: Placebo Biological: BCG Ovarian cancer" exact="Primary" post="peritoneal Drug: Pemetrexedâ€&quot;Phase 1 Drug: Carboplatinâ€&quot;Phase 1 Drug: Pemetrexedâ€&quot;Phase"/>
 <result pre="1 Drug: Carboplatinâ€&quot;Phase 1 Drug: Pemetrexedâ€&quot;Phase 2 Drug: Carboplatinâ€&quot;Phase 2" exact="Non-small cell lung cancer" post="Drug: Pazopanib Drug: Paclitaxel Non small lung cancer Drug:"/>
 <result pre="Carboplatinâ€&quot;Phase 1 Drug: Pemetrexedâ€&quot;Phase 2 Drug: Carboplatinâ€&quot;Phase 2 Non-small cell" exact="lung cancer" post="Drug: Pazopanib Drug: Paclitaxel Non small lung cancer Drug:"/>
 <result pre="1 Drug: Pemetrexedâ€&quot;Phase 2 Drug: Carboplatinâ€&quot;Phase 2 Non-small cell lung" exact="cancer" post="Drug: Pazopanib Drug: Paclitaxel Non small lung cancer Drug:"/>
 <result pre="Non-small cell lung cancer Drug: Pazopanib Drug: Paclitaxel Non small" exact="lung cancer" post="Drug: Pemetrexed Drug: Cisplatin Drug: Rabusertib (LY2603618) Pancreatic cancer"/>
 <result pre="cell lung cancer Drug: Pazopanib Drug: Paclitaxel Non small lung" exact="cancer" post="Drug: Pemetrexed Drug: Cisplatin Drug: Rabusertib (LY2603618) Pancreatic cancer"/>
 <result pre="lung cancer Drug: Pemetrexed Drug: Cisplatin Drug: Rabusertib (LY2603618) Pancreatic" exact="cancer" post="Drug: Vantictumab (OMP-18RS) Drug: Nab-paclitaxel Drug: Gemcitabine Integrative synergistic"/>
 <result pre="and promising in the treatment of diseases such as cancer," exact="cardiovascular" post="and gastrointestinal disorders [18, 19]. The integral role of"/>
 <result pre="â€œgutâ€� microbiome in health and in treating many diseases, including" exact="cancer" post="is beginning to emerge as demonstrated by immune checkpoint"/>
 <result pre="addresses many of the precision medicine treatment benefits, it falls" exact="short" post="in addressing issues such as the multi-morbidity, impact of"/>
 <result pre="in addressing issues such as the multi-morbidity, impact of the" exact="disease" post="on the patientsâ€™ lives, their adaptability to the disease"/>
 <result pre="the disease on the patientsâ€™ lives, their adaptability to the" exact="disease" post="or other existing diseases, their family, their social life"/>
 <result pre="receptor positive (HR+), human EGFR 2 negative (HER2âˆ’) advanced or" exact="metastatic" post="breast cancer, for the treatment of breast cancer in"/>
 <result pre="positive (HR+), human EGFR 2 negative (HER2âˆ’) advanced or metastatic" exact="breast cancer," post="for the treatment of breast cancer in men [27,"/>
 <result pre="(HER2âˆ’) advanced or metastatic breast cancer, for the treatment of" exact="breast cancer" post="in men [27, 28]. The former FDA Commissioner, Dr."/>
 <result pre="advanced or metastatic breast cancer, for the treatment of breast" exact="cancer" post="in men [27, 28]. The former FDA Commissioner, Dr."/>
 <result pre="Network deploys plethoric â€œtoolsâ€� for â€œPoint-of-Care Decisionsâ€�, genetic markers for" exact="disease" post="risk prediction including prevention, tools about family history data,"/>
 <result pre="tools about family history data, pharmacogenomics data and refinement of" exact="disease" post="diagnosis. Similarly, IBM Watson Health in collaboration with Brigham"/>
 <result pre="and institutes have created open access networks such as the" exact="Cancer" post="Biomedical Informatics Grid (caBIG) and the Cancer Translational Research"/>
 <result pre="such as the Cancer Biomedical Informatics Grid (caBIG) and the" exact="Cancer" post="Translational Research Informatics Grid (caTrip) for the caBIG project"/>
 <result pre="National Institutes of Health (NIH), the NCI-MATCH, a precision medicine" exact="cancer" post="treatment clinical trial that is co-led by National Cancer"/>
 <result pre="medicine cancer treatment clinical trial that is co-led by National" exact="Cancer" post="Institute (NCI) and the ECOG-ACRIN Cancer Research Group. In"/>
 <result pre="is co-led by National Cancer Institute (NCI) and the ECOG-ACRIN" exact="Cancer" post="Research Group. In the NCI-MATCH trial, patients received therapy"/>
 <result pre="received therapy based on the genetic changes found in their" exact="tumor" post="as exemplified by the results from Arm H of"/>
 <result pre="effective in a trial of 35 patients having 17 distinct" exact="tumor" post="types [34]. Most recently, the studies [35] published by"/>
 <result pre="Whole Genome (PCAWG) consortium involving whole genome sequencing of 2658" exact="cancer" post="genomes demonstrated new information about cancer drivers from 38"/>
 <result pre="genome sequencing of 2658 cancer genomes demonstrated new information about" exact="cancer" post="drivers from 38 tumor types and identified potentially new"/>
 <result pre="cancer genomes demonstrated new information about cancer drivers from 38" exact="tumor" post="types and identified potentially new targets for precision medicine."/>
 <result pre="â€œRight-to-Tryâ€� experimental drugs in treating life threatening diseases such as" exact="cancer" post="will most likely favor the outcome and mitigate the"/>
 <result pre="accelerate drug development time; (ii) reduce drug development cost; (iii)" exact="lower" post="the cost of drugs; (iv) improve the durable response;"/>
 <result pre="insurance companies, including global policy development and implementation currently present" exact="limited" post="opportunities and many challenges for the â€œRight-to-Tryâ€� experimental drugs"/>
 <result pre="and its full impact on treating life-threatening diseases such as" exact="cancer" post="and infectious diseases such as COVID-19 remain to be"/>
 <result pre="full impact on treating life-threatening diseases such as cancer and" exact="infectious diseases" post="such as COVID-19 remain to be seen. One of"/>
 <result pre="unfolding during the current coronavirus pandemic crisis. Abbreviations ECMC Experimental" exact="Cancer" post="Medicine Center EGFR Epidermal growth factor receptor EHR Electronic"/>
 <result pre="factor receptor 2 IRB Institutional review board MERS Middle East" exact="respiratory" post="syndrome RNA Ribonucleic acid SFDA State Food and Drug"/>
 <result pre="receptor 2 IRB Institutional review board MERS Middle East respiratory" exact="syndrome" post="RNA Ribonucleic acid SFDA State Food and Drug Administration"/>
 <result pre="and Drugs Act of 1906: â€˜I aimed at the publicâ€™s" exact="heart" post="and by accident I hit it in the stomachAm"/>
 <result pre="medicine. 2012. https://www.ohe.org/publications/rd-cost-new-medicine. Accessed 7 Feb 2020. 9.TysomeJRLemoineNRWangYUpdate on oncolytic" exact="viral" post="therapyâ€&quot;targeting angiogenesisOnco Targets Ther201361031104010.2147/OTT.S4697423940420 10.JiaHKlingJChina offers alternative gateway for"/>
 <result pre="experimental drugsNat Biotechnol20062411711810.1038/nbt0206-11716465139 11.ZhangWLiLLiDLiuJLiXLiWXuXZhangMJChandlerLALinHHuAXuWLamDMThe first approved gene therapy product for" exact="cancer" post="Ad-p53 (gendicine): 12 years in the clinicHum Gene Ther.201829216017910.1089/hum.2017.21829338444"/>
 <result pre="21.GopalakrishnanVHelminkBASpencerCNReubenAWargoJAThe influence of the gut microbiome on cancer, immunity, and" exact="cancer" post="immunotherapyCancer Cell201833457058010.1016/j.ccell.2018.03.01529634945 22.Moor K, Heukels P, Kool M, Wijsenbeek"/>
 <result pre="M, Wijsenbeek M. Integrating patient perspectives into personalized medicine in" exact="idiopathic pulmonary fibrosis." post="https://www.researchgate.net/publication/321945065. Accessed 9 Jan 2020. 23.American College of Physicians."/>
 <result pre="Wijsenbeek M. Integrating patient perspectives into personalized medicine in idiopathic" exact="pulmonary" post="fibrosis. https://www.researchgate.net/publication/321945065. Accessed 9 Jan 2020. 23.American College of"/>
 <result pre="3 trial of Ibrance (palbocicilib) plus letrozole in ER+, HER2âˆ’" exact="metastatic" post="breast cancer confirm improvement in progression-free survival. https://www.pfizer.com/news/press-release/press-release-detail/updated_data_from_phase_3_trial_of_ibrance_palbociclib_plus_letrozole_in_er_her2_metastatic_breast_cancer_confirm_improvement_in_progression_free_survival. Accessed"/>
 <result pre="trial of Ibrance (palbocicilib) plus letrozole in ER+, HER2âˆ’ metastatic" exact="breast cancer" post="confirm improvement in progression-free survival. https://www.pfizer.com/news/press-release/press-release-detail/updated_data_from_phase_3_trial_of_ibrance_palbociclib_plus_letrozole_in_er_her2_metastatic_breast_cancer_confirm_improvement_in_progression_free_survival. Accessed 8 Mar"/>
 <result pre="of Ibrance (palbocicilib) plus letrozole in ER+, HER2âˆ’ metastatic breast" exact="cancer" post="confirm improvement in progression-free survival. https://www.pfizer.com/news/press-release/press-release-detail/updated_data_from_phase_3_trial_of_ibrance_palbociclib_plus_letrozole_in_er_her2_metastatic_breast_cancer_confirm_improvement_in_progression_free_survival. Accessed 8 Mar"/>
 <result pre="combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic" exact="breast cancer" post="in real-world settings in the US: results from the"/>
 <result pre="with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast" exact="cancer" post="in real-world settings in the US: results from the"/>
 <result pre="public health issues. 2019. https://www.hcinnovationgroup.com/analytics-ai/artifical-intelligence-machine-learning/news/21068437/ibm-watson-teams-with-vanderbilt-brigham-and-womens. Accessed 22 Feb 2020. 32.McConnellPDashRCChilukuriRPietrobonRJohnsonKAnnechianricoRCuticchiaJAThe" exact="cancer" post="translational research informatics platformBMC Med Inform Decis Mak200886010.1186/1472-6947-8-6019108734 33.https://www.ecmcnetwork.org.uk/."/>
 <result pre="4 Jan 2020. 34.Jessica Kent. NIH precision medicine trial releases" exact="cancer" post="study. 2019. https://healthitanalytics.com/news/nih-precision-medicine-trial-releases-cancer-study-results. Accessed 18 Jan 2020. 35.Pan-cancer analysis"/>
</results>
